PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2104849-13 1990 Chromatography studies with heparin-Sepharose indicated that at least some of the lipoprotein lipase in cld/cld cells was dimerized. Heparin 28-35 lipoprotein lipase Mus musculus 82-100 34580885-7 2022 As a result, the LPL activity in post-heparin plasma was substantially increased, and postprandial plasma triglyceride clearance was significantly enhanced, while plasma triglyceride levels were decreased. Heparin 38-45 lipoprotein lipase Mus musculus 17-20 35229724-7 2022 GPIHBP1 trafficking across ECs in the mutant mice was normalized by disrupting LPL-HSPG electrostatic interactions with either heparin or an AD peptide. Heparin 127-134 lipoprotein lipase Mus musculus 79-82 2753911-7 1989 This was shown in cells treated with heparin and cycloheximide to be equal to 1 for LPL antigen but significantly greater than 1 for LPL activity assayed under standard conditions. Heparin 37-44 lipoprotein lipase Mus musculus 84-87 2753911-7 1989 This was shown in cells treated with heparin and cycloheximide to be equal to 1 for LPL antigen but significantly greater than 1 for LPL activity assayed under standard conditions. Heparin 37-44 lipoprotein lipase Mus musculus 133-136 2753911-11 1989 The existence of an inhibitor of LPL activity has been excluded as well as that of an increase in the catalytic activity of LPL during its secretion, before or after exposure to heparin. Heparin 178-185 lipoprotein lipase Mus musculus 124-127 2753912-9 1989 Under heparin stimulation, quantitative secretion of the mature form of LPL takes place whereas the intracellular degradation is arrested. Heparin 6-13 lipoprotein lipase Mus musculus 72-75 2753912-10 1989 Heparin is able to mobilize intracellular LPL without changing the rate of LPL export from the endoplasmic reticulum to the cell surface. Heparin 0-7 lipoprotein lipase Mus musculus 42-45 4041471-10 1985 Thus, avian adipose lipoprotein lipase has been purified by a one-step immunoaffinity followed by a concentrating step on heparin-Sepharose 4B. Heparin 122-129 lipoprotein lipase Mus musculus 20-38 3499389-4 1987 LPS suppressed in a dose- and time-dependent manner the heparin-induced secretion of LPL from the macrophage-like tumor cell line J774.1 and from bone marrow derived mononuclear phagocytes (BMM). Heparin 56-63 lipoprotein lipase Mus musculus 85-88 2431720-6 1986 Incubation of the macrophages with heparin caused a marked increase in the secretion of lipoprotein lipase. Heparin 35-42 lipoprotein lipase Mus musculus 88-106 2431720-7 1986 Short incubations with heparin (5 min) caused a release of the enzyme into the media, while longer incubations caused a 2-8-fold increase in net lipoprotein lipase secretion which was maximal after 2-16 h depending on cell type, and persisted for 24 h. The effect of heparin was dose-dependent and specific (it was not duplicated by other glycosaminoglycans). Heparin 267-274 lipoprotein lipase Mus musculus 145-163 2431720-10 1986 The heparin-induced increase in lipoprotein lipase secretion was dependent on protein synthesis. Heparin 4-11 lipoprotein lipase Mus musculus 32-50 2431720-11 1986 The secretion of lipoprotein lipase by macrophages in response to low levels of heparin may be a significant factor in the formation of atherosclerotic lesions. Heparin 80-87 lipoprotein lipase Mus musculus 17-35 3828107-5 1986 The activity of lipoprotein lipase accumulated in the heparin-releasable fraction during differentiation was increased 2- to 3-fold and the intracellular enzyme was enhanced 15- to 20-fold by the addition of phenobarbital. Heparin 54-61 lipoprotein lipase Mus musculus 16-34 3756204-4 1986 Activities of both lipoprotein lipase and hepatic triacylglycerol lipase in the plasma after heparin injection were markedly lower in the W/WV mice than in the congenic normal mice, although activities of both lipoprotein lipase in the heart and adipose tissue and hepatic triacylglycerol lipase in the liver were not decreased. Heparin 93-100 lipoprotein lipase Mus musculus 19-37 3955063-9 1986 Heparin injected intraperitoneally increased plasma lipoprotein lipase activity to 152 mU/ml, but had no effect on plasma hepatic lipase activity, in unaffected mice. Heparin 0-7 lipoprotein lipase Mus musculus 52-70 3955063-12 1986 Heparin injection increased plasma lipoprotein lipase activity in cld/cld mice, but the increment was less than 10% of that in unaffected mice. Heparin 0-7 lipoprotein lipase Mus musculus 35-53 3510667-13 1986 Despite this lack of activation, the lipoprotein lipase molecule was able to migrate intracellularily and to undergo secretion after heparin stimulation of the tunicamycin-treated cells. Heparin 133-140 lipoprotein lipase Mus musculus 37-55 3884609-3 1985 These adipose cells were previously shown to secrete lipoprotein lipase during exposure to heparin. Heparin 91-98 lipoprotein lipase Mus musculus 53-71 7470199-0 1981 Effect of intrapulmonary heparin on lipoprotein lipase activity in mice. Heparin 25-32 lipoprotein lipase Mus musculus 36-54 7470199-1 1981 The lipoprotein lipase (LPL) activity obtained from the intrapulmonary administration of 2-10 mg of heparin in mice was compared with the same parameter measured for intravenously administered heparin. Heparin 100-107 lipoprotein lipase Mus musculus 4-22 7470199-1 1981 The lipoprotein lipase (LPL) activity obtained from the intrapulmonary administration of 2-10 mg of heparin in mice was compared with the same parameter measured for intravenously administered heparin. Heparin 100-107 lipoprotein lipase Mus musculus 24-27 7470199-3 1981 A relatively large dose of intrapulmonary heparin produced a peak LPL activity which was a third of the maximum response obtained from a small dose of i.v. Heparin 42-49 lipoprotein lipase Mus musculus 66-69 7470199-7 1981 administration of heparin produced dose-dependent increases in plasma LPL activity (correlation coefficient r = 0.9). Heparin 18-25 lipoprotein lipase Mus musculus 70-73 515019-0 1979 Quantitative aspects of lipoprotein lipase release by heparin in mice. Heparin 54-61 lipoprotein lipase Mus musculus 24-42 18845532-4 2008 Heparin is known to release LPL from its in vivo binding sites, allowing it to enter the plasma. Heparin 0-7 lipoprotein lipase Mus musculus 28-31 19542565-4 2009 ANGPTL4 potently inhibited nonstabilized LPL as well as heparin-stabilized LPL but not GPIHBP1-stabilized LPL. Heparin 56-63 lipoprotein lipase Mus musculus 75-78 19542565-4 2009 ANGPTL4 potently inhibited nonstabilized LPL as well as heparin-stabilized LPL but not GPIHBP1-stabilized LPL. Heparin 56-63 lipoprotein lipase Mus musculus 75-78 19542565-6 2009 ANGPTL3 also inhibited heparin-stabilized LPL but with less potency than nonstabilized LPL. Heparin 23-30 lipoprotein lipase Mus musculus 42-45 19369870-4 2009 The pattern of lipoprotein lipase (LPL) release into the plasma after an intravenous injection of heparin is abnormal in Gpihbp1-deficient mice, suggesting that GPIHBP1 plays a direct role in binding LPL within the tissues of mice. Heparin 98-105 lipoprotein lipase Mus musculus 15-33 19369870-4 2009 The pattern of lipoprotein lipase (LPL) release into the plasma after an intravenous injection of heparin is abnormal in Gpihbp1-deficient mice, suggesting that GPIHBP1 plays a direct role in binding LPL within the tissues of mice. Heparin 98-105 lipoprotein lipase Mus musculus 35-38 18845532-6 2008 Indeed, plasma LPL levels peaked very rapidly (within 1 min) after heparin in control mice. Heparin 67-74 lipoprotein lipase Mus musculus 15-18 18845532-7 2008 In contrast, plasma LPL levels in Gpihbp1(-/-) mice were much lower 1 min after heparin and increased slowly over 15 min. Heparin 80-87 lipoprotein lipase Mus musculus 20-23 18845532-11 2008 The differences in LPL release after intravenous heparin and Intralipid strongly suggest that GPIHBP1 represents an important binding site for LPL in vivo. Heparin 49-56 lipoprotein lipase Mus musculus 19-22 18845532-11 2008 The differences in LPL release after intravenous heparin and Intralipid strongly suggest that GPIHBP1 represents an important binding site for LPL in vivo. Heparin 49-56 lipoprotein lipase Mus musculus 143-146 30698048-4 2019 In fed mice, some LPL colocalized with the endothelial markers CD31 and GPIHBP1 and could be removed by perfusion with heparin, indicating a vascular location. Heparin 119-126 lipoprotein lipase Mus musculus 18-21 29371243-9 2018 Arterial macrophage numbers decreased after heparin-mediated LpL cell dissociation and by genetic knockout of arterial LpL. Heparin 44-51 lipoprotein lipase Mus musculus 61-64 23186339-7 2012 LPL was releasable by heparin, indicating localization on cell surfaces. Heparin 22-29 lipoprotein lipase Mus musculus 0-3 23186339-5 2012 Heparin injections were used to discriminate between intracellular and extracellular LPL. Heparin 0-7 lipoprotein lipase Mus musculus 85-88 18845532-5 2008 After an injection of heparin, we reasoned that LPL bound to GPIHBP1 in capillaries would be released very quickly, and we hypothesized that the kinetics of LPL entry into the plasma would differ in Gpihbp1(-/-) and control mice. Heparin 22-29 lipoprotein lipase Mus musculus 48-51 14643896-11 2004 Heparin-releasable LPL activity in heart was 1.8-fold higher in mice fasted for 6h compared to fed controls. Heparin 0-7 lipoprotein lipase Mus musculus 19-22 15701679-9 2005 Addition of either heparin or LpL inhibitor P407 to Intralipid-containing perfusate restored [14C]palmitate uptake and confirmed that Intralipid inhibition requires local LpL. Heparin 19-26 lipoprotein lipase Mus musculus 171-174 17303003-7 2007 In fatty milk-induced hyperlipidemic mice, the post-heparin plasma activities of lipoprotein lipase (LPL), hepatic lipase (HL), and total lipase (TL) significantly increased after treatment with 10-20 mg/kg osthole for 3 weeks (P< 0.05 or P< 0.01). Heparin 52-59 lipoprotein lipase Mus musculus 81-99 17303003-7 2007 In fatty milk-induced hyperlipidemic mice, the post-heparin plasma activities of lipoprotein lipase (LPL), hepatic lipase (HL), and total lipase (TL) significantly increased after treatment with 10-20 mg/kg osthole for 3 weeks (P< 0.05 or P< 0.01). Heparin 52-59 lipoprotein lipase Mus musculus 101-104 16508209-6 2006 In fact, lipoprotein lipase and hepatic lipase activities in the post-heparin plasma of Angptl3-null mice were 1.57 times and 1.42 times higher than those of wild-type mice, respectively. Heparin 70-77 lipoprotein lipase Mus musculus 9-27 16392680-5 2005 Treatment of normal mice with FR177391 resulted in an increase in heparin-releasable lipoprotein lipase (LPL) activity in the blood and epididymal fat tissue. Heparin 66-73 lipoprotein lipase Mus musculus 105-108 15085072-6 2004 P-407 directly inhibits the heparin-releasable fraction of LPL and HL and indirectly increases the biologic activity of CETP and LCAT. Heparin 28-35 lipoprotein lipase Mus musculus 59-62 14570890-0 2004 Mice expressing only covalent dimeric heparin binding-deficient lipoprotein lipase: muscles inefficiently secrete dimeric enzyme. Heparin 38-45 lipoprotein lipase Mus musculus 64-82 14570890-3 2004 By creating a mouse line that expresses covalent dimers of heparin-binding deficient LpL (hLpLHBM-Dimer) in muscle, we confirmed in vivo that linking two LpL monomers in a head to tail configuration creates a functional LpL. Heparin 59-66 lipoprotein lipase Mus musculus 85-88 14570890-3 2004 By creating a mouse line that expresses covalent dimers of heparin-binding deficient LpL (hLpLHBM-Dimer) in muscle, we confirmed in vivo that linking two LpL monomers in a head to tail configuration creates a functional LpL. Heparin 59-66 lipoprotein lipase Mus musculus 91-94 14570890-3 2004 By creating a mouse line that expresses covalent dimers of heparin-binding deficient LpL (hLpLHBM-Dimer) in muscle, we confirmed in vivo that linking two LpL monomers in a head to tail configuration creates a functional LpL. Heparin 59-66 lipoprotein lipase Mus musculus 91-94 11440913-3 2001 This heparin-releasable LPL pool remained constant over a variety of experimental conditions, including workload and fatty acid concentrations, making the mouse heart a suitable model to study chylomicron catabolism. Heparin 5-12 lipoprotein lipase Mus musculus 24-27 12612134-9 2003 In mice, CLA-induced inhibition of heparin-releasable LPL and glucose metabolism may be the most important early steps leading to subsequent body fat reduction. Heparin 35-42 lipoprotein lipase Mus musculus 54-57 12388125-5 2003 Inhibition of lipoprotein lipase (LPL) with tetrahydrolipstatin or dissociation of LPL from the heart with heparin reduced cardiac uptake of TG by 82 and 64%, respectively (P < 0.01). Heparin 107-114 lipoprotein lipase Mus musculus 83-86 12190995-14 2002 The LPL activity was increased in post-heparin plasma and epididymal fat of treated db/db mice. Heparin 39-46 lipoprotein lipase Mus musculus 4-7 12549600-7 2003 Preinjection of heparin reduced heart and adipose uptakes of FO and MCT:LCT:FO emulsions with increased uptake by liver, suggesting a role of lipoprotein lipase in catabolism of FO-containing emulsions. Heparin 16-23 lipoprotein lipase Mus musculus 142-160 7759497-8 1995 Plasma heparin-releasable LPL activity was 43% lower in +/- versus +/+ adult animals. Heparin 7-14 lipoprotein lipase Mus musculus 26-29 11342582-3 2001 Three basic amino acids in the carboxyl terminal region of LpL were mutated, yielding an active enzyme with reduced heparin binding. Heparin 116-123 lipoprotein lipase Mus musculus 59-62 11342582-8 2001 Thus, heparin association is required for LpL stability and normal physiologic functions. Heparin 6-13 lipoprotein lipase Mus musculus 42-45 9505144-3 1998 The suppression of heparin-releasable LPL activity produced by combinations of IL-1 and IL-11, IL-1 and TNF-alpha, IL-11 and TNF-alpha, and, IL-11 and INF-gamma was substantially lower than that expected from the additive action of the corresponding two cytokines. Heparin 19-26 lipoprotein lipase Mus musculus 38-41 9034134-3 1997 A subsequent treatment of the tissues with 1 microg/ml PRL caused a 76% increase in heparin-releasable LPL (hrLPL) activity after 24 hr. Heparin 84-91 lipoprotein lipase Mus musculus 103-106 8157673-3 1994 Abundant hLPL transcripts were detected in RNA from different tissues of transgenic mice which resulted in an increase in post-heparin plasma LPL activity of approximately 154%. Heparin 127-134 lipoprotein lipase Mus musculus 10-13 7948751-4 1994 Recombinant murine D-factor produced a dose- and time-dependent inhibition of heparin-releasable LPL activity in differentiated 3T3-L1 adipocytes. Heparin 78-85 lipoprotein lipase Mus musculus 97-100 8279543-4 1993 With the use of a ligand blot method, LPL specifically bound to a heparin-releasable, 116-kDa protein on mouse-derived brown fat adipose cell (BFC-1 beta) and rat adipocyte membranes. Heparin 66-73 lipoprotein lipase Mus musculus 38-41 8135737-2 1994 Heparin-releasable and cell-associated LPL activity rose immediately after birth, followed 1-2 days later by an increase in LPL mRNA. Heparin 0-7 lipoprotein lipase Mus musculus 124-127 8135737-4 1994 During lactation, both milk and heparin-releasable LPL were substantially decreased by an overnight fast, whereas cell-associated LPL was less affected and LPL mRNA did not change. Heparin 32-39 lipoprotein lipase Mus musculus 51-54 8135737-5 1994 These studies indicate that the extracellular, heparin-releasable, fraction of mammary LPL activity responds most rapidly to alterations in physiological state, usually accompanied by smaller changes in cellular enzyme activity. Heparin 47-54 lipoprotein lipase Mus musculus 87-90 1638523-4 1992 Both human and murine IL-6 reduced heparin-releasable LPL activity in 3T3-L1 adipocytes in a dose-dependent manner; half-maximal inhibition of LPL activity was achieved with 5000 hybridoma growth factor units/ml. Heparin 35-42 lipoprotein lipase Mus musculus 54-57 8509711-8 1993 The addition of heparin to J774 cells resulted in a 6-fold increase in lipoprotein lipase (LPL) activity in the media, and significantly enhanced the ability of Type IV VLDL to induce cellular triglyceride accumulation (P < 0.01), but significantly decreased cellular cholesteryl ester content (P < 0.025). Heparin 16-23 lipoprotein lipase Mus musculus 71-89 8509711-8 1993 The addition of heparin to J774 cells resulted in a 6-fold increase in lipoprotein lipase (LPL) activity in the media, and significantly enhanced the ability of Type IV VLDL to induce cellular triglyceride accumulation (P < 0.01), but significantly decreased cellular cholesteryl ester content (P < 0.025). Heparin 16-23 lipoprotein lipase Mus musculus 91-94 1638523-4 1992 Both human and murine IL-6 reduced heparin-releasable LPL activity in 3T3-L1 adipocytes in a dose-dependent manner; half-maximal inhibition of LPL activity was achieved with 5000 hybridoma growth factor units/ml. Heparin 35-42 lipoprotein lipase Mus musculus 143-146